Proceeds expected to support a focused pulmonary hypertension strategy, including a Phase 1b proof-of-concept study evaluating Auxora™ in PAH, with data anticipated mid-2027, and advancement of oral CRAC channel inhibitor CM5480 to IND clearance expected mid-2027 Anticipated cash runway...
Hence then, the article about calcimedica announces private placement financing for up to approximately 49 million to advance pulmonary hypertension program was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program )
Also on site :
- A New Chapter of Intimate Luxury in Ubud: The Kayon Resort Introduces Premier Pool Villa & Royal Jacuzzi Pool Villa
- ’70s Rock Legends’ Sons, Carrying the Allman Brothers’ Torch, Announce 2026 Tour With All-Star Guests
- Walmart’s $18 4-Pack of Motion-Activated Solar Lights Are a Bright Idea for Your Deck, Driveway, and Porch